Collectively, these findings underscore BMI1 as a pivotal therapeutic target in NPC, offering a strategic avenue to disrupt tumor progression, metastasis, and therapy resistance while improving clinical outcomes. The gene discussed is BMI1; the disease is nasopharyngeal carcinoma.